

Future upcoming technologies and what audit needs to address

Dr R.I MacKay

The Christie NHS Foundation Trust



History of audit

- Absolute dose
 - Simple phantom standard dose measurement
- Point doses in beams
 - Phantoms of relatively simple geometry
 - Several points in beam
- Treatment simulation
 - Point doses
 - Semi anatomical phantom
 - Realistic treatment technique
 - Scan – Plan - Treat
- IMRT
 - Absolute dose and dose distribution
 - More complex treatment protocol
- Rotational Audit
 - Challenging geometry
 - Test of planning system and dose delivery
- Advanced techniques
 - SABR





Figure 2. The field arrangement and a typical dose distribution for the planned irradiation showing the positions of the five measurement points.



Advanced Radiotherapy

| Modality | Small field | High Intensity Modulation | Adaptive Radiotherapy | Imaging | High dose rate | Gating/Tracking |
|------------------------|-------------|---------------------------|-----------------------|---------|----------------|-----------------|
| Protons | | √ | √ | √ | | ? |
| Flattening Filter Free | | √ | √ | √ | √ | |
| VMAT | | √ | √ | √ | √ | |
| Cyber Knife | √ | √ | | √ | | √ |
| Tomotherapy | | √ | √ | √ | | |
| SRS Linac | √ | | | √ | | |
| MR linac | | √ | √ | √ | | √ |

Challenges in new technology


- Technology is making dose delivery more diverse
- New technology is a combination of advanced delivery techniques
- Audit is traditionally quite rigid
 - We design the audit for the technique
- Does this fit our model of regional audit
 - Collaborative approaches between those with similar technology




Can we make the measurement system more flexible

Marvin: Overview

- Model
Anatomy for
Radiotherapy
Verification and Audit
In the Head and
Neck







- Average geometry from patient CT scans (4 male, 4 female):
 - Body
 - Mandible
 - Sinuses
 - Spinal cord (location only)
- Mandible and cavity can be swapped for ABS versions to make a homogeneous phantom




Marvin: Detector module

- Cylindrical detector module
 - Location maximises coverage of typical PTV locations and spinal cord
 - Can be designed for any type of detector (film, gel, diode array...)
- Prototype module designed for pinpoint ionisation chamber
 - Absolute dose measurements
- Simple chamber positioning system
 - 15 chamber holes from centre to edge
 - Module rotates to 12 fixed positions
 - Depth of chamber set using spacer rodsChamber can be positioned almost anywhere within the cylinder




Chamber positioning code

- Need to be able to position chamber:
 - Within the PTV or spinal cord
 - Avoid steep dose gradients
- Detector module has >1500 possible chamber positions
 - Selecting suitable points manually can be difficult
- Software automates point selection
 - PTV located as a percentage of the max dose point (typically 90 or 95 %)
 - Cord position known from average cord geometry
 - Chamber positions lying within these regions and with low dose gradients identified
 - Code currently based on Pinnacle file format




Example audit results






Phantom Free Audit ?




• 2D DGRT – VMAT verification




• 3D DGRT – Dose reconstruction



• 2D DGRT – Trend analysis



Delineation variation: CT versus CT + PET



•Steenbakkers et al, IJROBP 2005
The Christie **NHS**
NHS Foundation Trust

Potential uses of PET in RT planning

1. Improved diagnosis and staging of disease
 - Improved sensitivity and specificity of FDG-PET
 - Can detect distant metastasis and advanced disease

TABLE 1
Comparison of CT and ¹⁸F-FDG PET for Staging of Lymph Node Involvement

| Cancer (reference[s]) | % Sensitivity | | % Specificity | |
|----------------------------|---------------|-------------------------|---------------|-------------------------|
| | CT | ¹⁸ F-FDG PET | CT | ¹⁸ F-FDG PET |
| Head and neck (19–25) | 36–86 | 50–96 | 56–100 | 88–100 |
| NSCLC (27–31) | 45 | 80–90 | 85 | 85–100 |
| Cervical carcinoma (34–36) | 57–73* | 75–91 | 83–100* | 92–100 |
| Esophageal (32) | 11–87 | 30–78 | 28–99 | 86–98 |


*CT or MRI.

- Gregoire et al, J Nuc Med 48(1)S, 2007



Potential uses of PET in RT planning

2. Tumour delineation





- Tumour boundary

- Involved lymph nodes (10-25%)



Potential uses of PET in RT planning

3. Dose modulation




- Targeted conformal high dose
- Isotoxic dose escalation
- Improved local control with no increase in toxicity?



4. Prediction / monitoring treatment response

Transfer of Information



Site Approval


PET Centre: **WMIC**
 Scanner Manufacturer and Model: **Siemens Biograph TrueV6**
 Analysis performed by: **LP**
 Date of Phantom Analysis: **06/04/2011**

Qualitative Analysis:

| | | |
|---|--|----------------|
| Image Quality | Acceptable | Not acceptable |
| PET/CT alignment on core centre reporting system | Acceptable | Not acceptable |
| Comments | analysed on Hermes Gold 3 hybrid viewer. | |
| Sphere activity concentration at scan start time: | 21.60 | kBq/ml |
| Background activity concentration at scan start time: | 4.45 | kBq/ml |

| Sphere diameter (mm) | Activity Concentration | | |
|----------------------|------------------------|-------------------|-----------|
| | Measured (M) kBq/ml | Actual (A) kBq/ml | Ratio M/A |
| 37 | 21.72 | 21.60 | 1.01 |
| 28 | 22.88 | 21.60 | 1.06 |
| 22 | 22.00 | 21.60 | 1.02 |
| 17 | 18.43 | 21.60 | 0.85 |
| 13 | 15.36 | 21.60 | 0.71 |
| 10 | 8.05 | 21.60 | 0.37 |
| Background | 4.03 | 4.45 | 0.90 |

A recovery curve should be generated from the tabulated data:



Average SUV for a large ROI positioned over the background: 0.91 (1±0.1)

| | | |
|-----------------|------------|----------------|
| Recovery Curve: | Acceptable | Not acceptable |
|-----------------|------------|----------------|





Protons

- Uncertainties in proton therapy are greater
 - Uncertainty in proton stopping power
 - Inhomogeneities
 - Set up uncertainties have a greater effect
 - Changes in patient anatomy
- Dose delivery for scanned beams is highly intensity modulated using very small delivery fields
 - Motion is a well known problem in scanning proton therapy
- Dose delivery for IMPT is not in itself robust
- Require dosimetry for protons at same level of photons




Audit for proton therapy



- Validation (4D dosimetry)

csem

- Introducing 'Oscar' – a 4D, anthropomorphic phantom




• Zakova et al, P142, PTCOG 52



- Validation (4D dosimetry)

csem

- 4D CT of 'Oscar'




• Zakova et al, P142, PTCOG 52



- Validation (4D dosimetry)
- 'Oscar' has been irradiated

• 45s irradiation with protons (Gantry 1)



• Zakova et al, P142, PTCOG 52



Where will it end?



Summary

- Dosimetric audit is a powerful tool and has served radiotherapy well
- Treatment techniques become more diverse as technology progresses and audit must become more flexible
- Greater collaboration between users of particular delivery systems
- Need to extend the audit process to include additional information that will increasingly affect how we deliver radiotherapy
 - Particularly functional imaging
- Require dosimetry for protons at same level of photons.
 - New tools for audit required

